Featured Research

from universities, journals, and other organizations

Babies born just two or three weeks early at higher risk of poor health

Date:
March 2, 2012
Source:
BMJ-British Medical Journal
Summary:
New research demonstrates that babies born even just a few weeks early have worse health outcomes than full-term babies.

Babies born even just a few weeks early have worse health outcomes than full term babies.
Credit: Dmitry Pichugin / Fotolia

A research paper which demonstrates that babies born even just a few weeks early have worse health outcomes than full term babies has been published on the British Medical Journal website.

The authors, from the Universities of Leicester, Liverpool, Oxford, Warwick and the National Perinatal Epidemiology Unit studied over 18,000 British babies born between September 2000 and August 2001. Health outcomes were studied when the infants reached nine months, three years and five years.

Health outcomes assessed included height, weight and BMI, whilst parents also reported on number of hospital visits, long-standing illness, disability or infirmity, wheezing, use of prescribed medication and overall rating of child's health.

The authors report that both moderate / late preterm (32-36 weeks) and early term (37-38 weeks) babies required re-admission to hospital in the first few months more often than full term babies (39-41 weeks). Those born between 33 and 36 weeks had an increased risk of asthma and wheezing compared to full term babies.

A strong correlation was found between decreasing gestation and increasing risk of poor health outcomes. The greatest contribution to disease at the age of both three and five was being born moderate / late preterm or early term. The study discovered that mothers of children born at less than 37 weeks were more likely to be single, less likely to have educational qualifications or work in managerial positions. Mothers of very preterm babies were more likely to smoke and less likely to breast feed for four or more months than those delivered at or beyond 37 weeks.

The authors conclude that it is inappropriate simply to group babies as preterm or term as the study demonstrates a "continuum of increasing risk of adverse outcome with increasing prematurity, even approaching full term gestation." They argue for further explanation of factors that influence health outcomes for babies born between 32-38 weeks gestation to inform the provision of obstetric services and planning and delivery of healthcare services for children in early life.


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. E. M. Boyle, G. Poulsen, D. J. Field, J. J. Kurinczuk, D. Wolke, Z. Alfirevic, M. A. Quigley. Effects of gestational age at birth on health outcomes at 3 and 5 years of age: population based cohort study. BMJ, 2012; 344 (mar01 2): e896 DOI: 10.1136/bmj.e896

Cite This Page:

BMJ-British Medical Journal. "Babies born just two or three weeks early at higher risk of poor health." ScienceDaily. ScienceDaily, 2 March 2012. <www.sciencedaily.com/releases/2012/03/120302083228.htm>.
BMJ-British Medical Journal. (2012, March 2). Babies born just two or three weeks early at higher risk of poor health. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/03/120302083228.htm
BMJ-British Medical Journal. "Babies born just two or three weeks early at higher risk of poor health." ScienceDaily. www.sciencedaily.com/releases/2012/03/120302083228.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins